Global Protein Therapeutics Market Analysis

Table of Contents

1. Analyst View

2. Global Proteins Therapeutic Market

• 2.1 Market Analysis
  • 2.1.1 Market Size
  • 2.1.2 Proteins Therapeutic Market vs Pharmaceutical Market
  • 2.1.3 Market Segmentation
• 2.2 Future Outlook (2010-2012)

3. Industry Performance

• 3.1 Monoclonal Antibodies (mAb)
  • 3.1.1 Market Size
  • 3.1.2 By Application
  • 3.1.3 Key Geographical Markets
  • 3.1.4 Key Players and Drugs
  • 3.1.5 Industry Analysis
  • 3.1.6 Future Outlook (2010-2012)
• 3.2 Erythropoietin (EPO)
  • 3.2.1 Market Size
  • 3.2.2 By Application
  • 3.2.3 Key Geographical Markets
  • 3.2.4 Key Players and Drugs
  • 3.2.5 Industry Analysis
  • 3.2.6 Future Outlook (2010-2012)
• 3.3 Insulin
  • 3.3.1 Market Size
  • 3.3.2 By Application
  • 3.3.3 Key Geographical Markets
  • 3.3.4 Key Players and Drugs
  • 3.3.5 Industry Analysis
  • 3.3.6 Future Outlook (2010-2012)
• 3.4 Interferon (IFN)
  • 3.4.1 Market Size
  • 3.4.2 Key Geographical Markets
  • 3.4.3 Key Players and Drugs
  • 3.4.4 Industry Analysis
  • 3.4.5 Future Outlook (2010-2012)
• 3.5 Human Growth Hormone (HGH)
  • 3.5.1 Market Size
  • 3.5.2 By Application
  • 3.5.3 Key Geographical Markets
  • 3.5.4 Key Players and Drugs
  • 3.5.5 Industry Analysis
  • 3.5.6 Future Outlook (2010-2012)
• 3.6 Blood Clotting Factor
  • 3.6.1 Market Size
  • 3.6.2 Key Players and Drugs
  • 3.6.3 Industry Analysis
  • 3.6.4 Future Outlook (2010-2012)
• 3.7 Follicle Stimulating Hormone (FSH)
  • 3.7.1 Market Size
  • 3.7.2 Key Players and Drugs
  • 3.7.3 Industry Analysis
  • 3.7.4 Future Outlook (2010-2012)
• 3.8 Granulocyte Colony Stimulating Factor (G-CSF)
  • 3.8.1 Market Size
  • 3.8.2 Key Players and Drugs
  • 3.8.3 Industry Analysis
  • 3.8.4 Future Outlook (2010-2012)

4. Emerging Market Trends

• 4.1 Biogenerics
• 4.2 Contract Research Outsourcing
• 4.3 Contract Manufacturing
• 4.4 Nanotechnology-enabled Drug Delivery Market
• 4.5 Healthcare Insurance
• 4.6 High Approval Rate

5. Growth Inhibitors

• 5.1 High R&D Cost
• 5.2 High Price
• 5.3 High Failure Rates in Phase-3 Clinical Trials
• 5.4 Insurance Reimbursements
• 5.5 Lack of Predictability in the Operating Environment

6. Key Players

• 6.1 Johnson & Johnson
• 6.2 Biogen Idec Inc.
• 6.3 Eli Lilly & Company
• 6.4 Novo Nordisk A/S
• 6.5 Sanofi-Aventis
• 6.6 Roche Group
• 6.7 Amgen Inc.
• 6.8 Genentech, Inc.
• 6.9 Merck Serono S.A.

List of Figures:

• Figure 2-1: Global - Proteins Therapeutic Market (Billion US$), 2007-2009
• Figure 2-2: Global - Comparison of Proteins Therapeutic Market to Pharmaceutical Market (Billion US$), 2007 & 2008
• Figure 2-3: Global - Proteins Therapeutic Market by Segment (%), 2008
• Figure 2-4: Global - Forecast for Proteins Therapeutic Market (Billion US$), 2010-2012
• Figure 2-5: Global - Forecast for Proteins Therapeutic Market by Segment (%), 2012
• Figure 3-1: Global - Monoclonal Antibodies Market (Billion US$), 2007-2009
• Figure 3-2: Global - Monoclonal Antibodies Market in Cancer Treatment (Billion US$), 2007-2009
• Figure 3-3: Global - Monoclonal Antibodies Market in Rheumatoid Arthritis Treatment (Billion US$), 2007-2009
• Figure 3-4: Global - Monoclonal Antibodies Market in Cardiovascular and Infectious Diseases Treatment (Billion US$), 2008
• Figure 3-5: Global - Monoclonal Antibodies Market in Cardiovascular and Infectious Diseases Treatment (Billion US$), 2009
• Figure 3-6: US - Monoclonal Antibodies Market (Billion US$), 2007-2009
• Figure 3-7: US - Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2012
• Figure 3-8: Europe - Monoclonal Antibodies Market (Billion US$), 2007-2009
• Figure 3-9: Europe - Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2012
• Figure 3-10: Europe - Forecast for Monoclonal Antibodies Market by Application (%), 2011
• Figure 3-11: Japan - Monoclonal Antibodies Market (Billion JPY), 2007-2009
• Figure 3-12: Japan - Forecast for Monoclonal Antibodies Market (Billion JPY), 2010-2012
• Figure 3-13: Global - Share of Key Players in Monoclonal Antibodies Market (2008)
• Figure 3-14: Global - Top Selling Monoclonal Antibodies (Billion US$)
• Figure 3-15: Global - Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2012
• Figure 3-16: Global - Erythropoietin Market (Billion US$), 2006-2009
• Figure 3-17: Global - First Generation Erythropoietin Market (Billion US$), 2006-2009
• Figure 3-18: Global - First Generation Erythropoietin Alpha Market (Million US$), 2006-2009
• Figure 3-19: Global - First Generation Erythropoietin Beta Market (Million US$), 2006-2009
• Figure 3-20: Global - Second Generation Erythropoietin Market (Billion US$), 2006-2009
• Figure 3-21: Global - Number of Patients on Dialysis (Million), 2007-2009
• Figure 3-22: Global - Breakup of Patients on Dialysis by Region (%), 2008
• Figure 3-23: Global - Number of New Cancer Cases (Million), 2008 & 2030
• Figure 3-24: Global - Breakup of New Cancer Cases by Region (%), 2008
• Figure 3-25: Europe - Erythropoietin & Untapped Erythropoietin Market for Chemotherapy (Million Euro), 2004
• Figure 3-26: US - Share in Global Erythropoietin Market (%), 2008
• Figure 3-27: Europe - Erythropoietin Market (Billion US$), 2007-2009
• Figure 3-28: Europe - Forecast for Erythropoietin Market (Billion US$), 2010-2012
• Figure 3-29: Europe - Erythropoietin Market in Renal Anemia Treatment (Million US$), 2007-2009
• Figure 3-30: Europe - Erythropoietin Market in Oncology Treatment (Million US$), 2007-2009
• Figure 3-31: Europe - First Generation Erythropoietin Patent Expiry by Major Country
• Figure 3-32: Japan - Erythropoietin Market (Billion JPY), 2007-2009
• Figure 3-33: Global - Forecast for Erythropoietin Market (Billion US$), 2010-2012
• Figure 3-34: Europe - Forecast for Share of Oncology and Renal Anemia in Erythropoietin Market (%), 2016
• Figure 3-35: Global - Insulin Market (Billion US$), 2006-2009
• Figure 3-36: India - Number of Diabetic Patients (Million), 2008 & 2030
• Figure 3-37: India - Insulin Market (Million US$), 2007-2009
• Figure 3-38: India - Share of Key Players in Insulin Market
• Figure 3-39: China - Insulin Market (Billion RMB), 2006-2009E
• Figure 3-40: China - Share of Key Players in Insulin Market (Q3 2008)
• Figure 3-41: US - Insulin Market (Billion US$), 2002-2006
• Figure 3-42: US - Share of Key Players in Insulin Market (2008)
• Figure 3-43: Russia - Insulin Market (Million US$), 2007-2009
• Figure 3-44: Russia - Share of Key Players in Insulin Market (H1 2006)
• Figure 3-45: Russia - Insulin Market by Channel of Sales (%), 2007
• Figure 3-46: Japan - Insulin Market (Billion JPY), 2007-2009
• Figure 3-47: Japan - Share of Key Players in Insulin Market (2008)
• Figure 3-48: Germany - Share of Insulin in Genetically Manufactured Pharmaceuticals Market (2007)
• Figure 3-49: Brazil - Insulin Market (Million BRL), 2007-2009
• Figure 3-50: Brazil - Share of Key Players in Insulin Market (2007)
• Figure 3-51: Global - Share of Key Players in Insulin Market (2008)
• Figure 3-52: Share of Novo Nordisk in the Insulin Market of US, Europe and Japan (2008)
• Figure 3-53: Global - Share of Brands in Insulin Market (2008)
• Figure 3-54: Global - Number of Diabetic Patients (Million), 2007 & 2025
• Figure 3-55: Global - Forecast for Insulin Market (Billion US$), 2010-2012
• Figure 3-56: Global - Interferon Market (Billion US$), 2007-2009
• Figure 3-57: Global - Share of Alpha and Beta in Interferon Market (2008)
• Figure 3-58: Global - Interferon Alpha Market (Billion US$), 2007-2009
• Figure 3-59: Global - Forecast for Hepatitis B Treatment Market (Billion US$), 2010-2015
• Figure 3-60: Global - Hepatitis C Treatment Market (Billion US$), 2007-2009
• Figure 3-61: Global - Forecast for Hepatitis C Treatment Market (Billion US$), 2010-2015
• Figure 3-62: Global - Forecast for Share of Interferon in Hepatitis C Treatment Market (2015)
• Figure 3-63: Global - Interferon Beta Market (Billion US$), 2007-2009
• Figure 3-64: Global - Multiple Sclerosis Treatment Market (Billion US$), 2007-2009
• Figure 3-65: US - Interferon Market (Billion US$)
• Figure 3-66: Europe - Interferon Market (Million US$)
• Figure 3-67: Japan - Interferon Market (Billion JPY), 2007-2009
• Figure 3-68: Global - Forecast for Interferon Market (Billion US$), 2010-2012
• Figure 3-69: Global - Human Growth Hormone Market (Billion US$), 2007-2009
• Figure 3-70: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (‘000)
• Figure 3-71: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature (2006)
• Figure 3-72: Global - Adult Growth Hormone Deficiency Market (Million US$), 2006
• Figure 3-73: Global - Human Growth Hormone Market by Region (%), 2007
• Figure 3-74: US - Human Growth Hormone Market (Billion US$), 2007-2009
• Figure 3-75: Japan & Europe - Human Growth Hormone Market (Million US$), 2007
• Figure 3-76: Global - Share of Key Players in Human Growth Hormone Market (2008)
• Figure 3-77: Global - Forecast for Human Growth Hormone Market (Billion US$), 2010-2012
• Figure 3-78: Global - Blood Clotting Factor Market (Billion US$), 2007-2009
• Figure 3-79: Global - Share of Blood Clotting Factor Market by Segment (2008)
• Figure 3-80: Global - Share of Key Players in Blood Clotting Factor Market (2008)
• Figure 3-81: Global - Forecast for Blood Clotting Factor Market (Billion US$), 2010-2012
• Figure 3-82: Global - Follicle Stimulating Hormone Market (Billion US$), 2007-2009
• Figure 3-83: Global - Forecast for Follicle Stimulating Hormone Market (Billion US$), 2010-2012
• Figure 3-84: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2007-2009
• Figure 3-85: US - Share in Global Granulocyte Colony Stimulating Factor Market
• Figure 3-86: Global - Forecast for Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2012
• Figure 4-1: Global - Sales of Biologics by Year of Patent Expiration (Billion US$), 2008-2015
• Figure 4-2: Global - Biogenerics Market (Billion US$), 2007 & 2011
• Figure 4-3: Global - Contract Research Outsourcing Market (Billion US$), 2008 & 2013
• Figure 4-4: Global - Market for Pharmaceutical Contract Manufacturing (Billion US$), 2008-2012
• Figure 4-5: Global - Nanotechnology-enabled Drug Delivery Market (Billion US$), 2007 & 2012
• Figure 4-6: Global - Health Insurance Market (Billion US$), 2008-2012
• Figure 4-7: Global - Approval Rate for Biopharmaceuticals and Conventional Pharmaceuticals
• Figure 5-1: Global - Comparison of Annual Cost of Biotech Drugs to Traditional Drugs (US$), 2006
• Figure 5-2: Global - Failure Rate in Phase-3 Clinical Trials of Biotech and Traditional Drugs

List of Tables:

• Table 3-1: Global - Key Players and Drugs in Erythropoietin Alpha Market (Billion US$), 2008
• Table 3-2: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2008
• Table 3-3: Global - Key Players and Drugs in Darbepoetin Alpha Market (Billion US$), 2008
• Table 3-4: China - Diabetic Patients in Age Group 20-79 Years (‘000), 2007
• Table 3-5: China - Forecast for Diabetic Patients in Age Group 20-79 Years (‘000), 2025
• Table 3-6: US - Diabetic Patients in Age Group 20-79 Years (' 000), 2007
• Table 3-7: US - Forecast for Diabetic Patients in Age Group 20-79 Years (‘000), 2025
• Table 3-8: Russia - Diabetic Patients in Age Group 20-79 Years (' 000), 2007
• Table 3-9: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years (‘000), 2025
• Table 3-10: Japan - Diabetic Patients in Age Group 20-79 Years (' 000), 2007
• Table 3-11: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years (' 000), 2025
• Table 3-12: Germany - Diabetic Patients in Age Group 20-79 Years (' 000), 2007
• Table 3-13: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years (' 000), 2025
• Table 3-14: Brazil - Diabetic Patients in Age Group 20-79 Years (' 000), 2007
• Table 3-15: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years (' 000), 2025
• Table 3-16: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2008
• Table 3-17: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2008
• Table 3-18: Global - Key Players and Drugs in Human Growth Hormone Market (Million US$), 2008
• Table 3-19: Global - Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2008
• Table 3-20: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2008
• Table 3-21: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2008
• Table 4-1: US & Europe - Patent Expiry Dates for Recombinant Biologics
• Table 4-2: US & EU - Forecast for Biogenerics Market by Segment (Million US$), 2010